Nasdaq Issues Delisting Notice to Heron Therapeutics for Sub-$1.00 Stock Price
HRTX is trading near its 52-week low of $0.382 (7.3% above the low).
Summary
Heron Therapeutics received a formal delisting notice from Nasdaq due to its stock trading below $1.00, initiating a 180-day period to regain compliance.
Key Events · Legal and Risk Events · HRTX
-
Formal Nasdaq Delisting Notice Received
Heron Therapeutics received a notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement for continued listing.
-
180-Day Compliance Period Initiated
The company has 180 calendar days, until December 22, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive days.
-
No Immediate Impact on Trading
The notice does not immediately affect the listing or trading of HRTX common shares on The Nasdaq Capital Market.
-
Potential Reverse Stock Split
If compliance is not met within the initial period, the company may be eligible for an additional 180 days, potentially requiring a reverse stock split.
Analysis · HRTX · Life Sciences
Heron Therapeutics has received a formal notice from Nasdaq regarding its failure to meet the minimum $1.00 bid price requirement. This triggers a 180-day compliance period, during which the company must maintain a closing bid price of at least $1.00 for ten consecutive days to avoid potential delisting. This event follows a prior warning in the Q1 2026 earnings report and adds significant pressure on the company, especially after recent patent invalidation for its key product CINVANTI®.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HRTX was trading at $0.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $77.6M. The 52-week trading range was $0.38 to $2.30. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.